Study of BHV-1400 in IgA Nephropathy
NCT07054684
This study is recruiting at 14 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- IgA Nephropathy
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Biohaven Therapeutics Ltd.
- Last updated on ClinicalTrials.gov
- June 23, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 1
- Site-001 · Farmington, CT
Florida · 4
- Site-003 · Miami Lakes, FL
- Site-011 · Miami Lakes, FL
- Site-013 · Orlando, FL
- Site-005 · Pembroke Pines, FL
Georgia · 1
- Site-008 · Lawrenceville, GA
Illinois · 1
- Site-009 · Hinsdale, IL
Indiana · 1
- Site-012 · Indianapolis, IN
Michigan · 1
- Site-015 · Shelby, MI
Missouri · 1
- Site-006 · Chesterfield, MO
South Dakota · 1
- Site-002 · Dakota Dunes, SD
Texas · 2
- Site-004 · Houston, TX
- Site-014 · Houston, TX
Utah · 1
- Site-016 · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.